Status:
COMPLETED
Hemodynamic-GUIDEd Management of Heart Failure
Lead Sponsor:
Abbott Medical Devices
Conditions:
Heart Failure
Heart Failure, Systolic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present...
Detailed Description
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including HF patients outside of the present indication, but...
Eligibility Criteria
Inclusion
- Diagnosis and treatment for heart failure (HF) (regardless of left ventricular ejection fraction (LVEF)) for \> 90 days prior to the date of consent:
- a. Subjects should be on stable, optimally titrated medical therapy for at least 30 days, as recommended according to current American Heart Association (AHA)/American College of Cardiology (ACC) guidelines as standard-of-care for HF therapy in the United States, with any intolerance documented.
- GUIDE-HF Randomized Arm Only: NYHA Class II, III or IV HF symptoms documented within 30 days prior to consent.
- GUIDE-HF Single Arm Only: NYHA Class III HF symptoms documented within 30 days prior to consent.
- HF hospitalization (HFH) within 12 months prior to consent and/or elevated N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) (or Brain Natriuretic Peptide (BNP)) within 30 days prior to consent defined as:
- Subjects with LVEF ≤ 40%: NT-proBNP ≥ 1000 pg/mL (or BNP ≥ 250 pg/mL).
- Subjects with LVEF \> 40%: NT-proBNP ≥ 700 pg/mL (or BNP ≥ 175 pg/mL).
- Thresholds for NT-proBNP and BNP (for both LVEF ≤ 40% and LVEF \> 40%) will be corrected for body mass index (BMI) using a 4% reduction per BMI unit over 25 kg/m2
- ≥ 18 years of age
- Chest circumference of \< 65 inches, if BMI is \> 35 kg/m2
- Written informed consent obtained from subject
- Willing and able to upload pulmonary artery (PA) pressure information and comply with the follow-up requirements
Exclusion
- Intolerance to all neuro-hormonal antagonists (i.e., intolerance to angiotensin converting enzyme-inhibitors (ACE-I), angiotensin receptor blockers (ARB), angiotensin-neprilysin inhibitors (ARNi), hydralazine/isosorbide dinitrate and beta-blockers)
- ACC/AHA Stage D refractory HF (including having received or currently receiving pharmacologic circulatory support with inotropes)
- Received or are likely to receive an advanced therapy (e.g., mechanical circulatory support or cardiac transplant) in the next 12 months
- NYHA Class IV HF patients with:
- Continuous or chronic use of scheduled intermittent inotropic therapy for HF and an INTERMACS level of ≤ 4, OR
- Persistence of fluid overload with maximum (or dose equivalent) diuretic intervention
- Glomerular Filtration Rate (eGFR) \< 25 mL/min and non-responsive to diuretic therapy, or receiving chronic dialysis
- Inability to tolerate or receive dual antiplatelet therapy or anticoagulation therapy for one month post-implantation
- Significant congenital heart disease that has not been repaired and would prevent implantation of the CardioMEMS™ PA Sensor
- Implanted with mechanical right heart valve(s)
- Unrepaired severe valvular disease
- Pregnant or planning to become pregnant in the next 12 months
- An active, ongoing infection, defined as being febrile, an elevated white blood cell count, on intravenous antibiotics, and/or positive cultures (blood, sputum or urine).
- History of current or recurrent (≥ 2 episodes within 5 years prior to consent) pulmonary emboli and/or deep vein thrombosis
- Major cardiovascular event (e.g., unstable angina, myocardial infarction, percutaneous coronary intervention, open heart surgery, or stroke, etc.) within 90 days prior to consent
- Implanted with Cardiac Resynchronization Therapy (CRT)-Pacemaker (CRT-P) or CRT-Defibrillator (CRT-D) for less than 90 days prior to consent
- Enrollment into another trial with an active treatment arm
- Anticipated life expectancy of \< 12 months
- Any condition that, in the opinion of the Investigator, would not allow for utilization of the CardioMEMS™ HF System to manage the subject using information gained from hemodynamic measurements to adjust medications, including the presence of unexpectedly severe pulmonary hypertension (e.g., trans-pulmonary gradient \>15) at implant right heart catheterization (RHC), a history of non-compliance, or any condition that would preclude CardioMEMS™ PA Sensor implantation
Key Trial Info
Start Date :
March 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 17 2023
Estimated Enrollment :
2358 Patients enrolled
Trial Details
Trial ID
NCT03387813
Start Date
March 15 2018
End Date
May 17 2023
Last Update
August 7 2025
Active Locations (129)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner-University Medical Center Phoenix
Phoenix, Arizona, United States, 85006
2
Arizona Cardiovascular Research Center
Phoenix, Arizona, United States, 85016
3
Phoenix Cardiovascular Research Group
Phoenix, Arizona, United States, 85018
4
University of Arizona
Tucson, Arizona, United States, 85719